Equities Analysts Issue Forecasts for THTX FY2025 Earnings

Theratechnologies Inc. (NASDAQ:THTX) – Equities researchers at Leede Financial cut their FY2025 earnings per share (EPS) estimates for Theratechnologies in a research note issued to investors on Wednesday, February 26th. Leede Financial analyst D. Loe now forecasts that the company will earn $0.06 per share for the year, down from their previous forecast of $0.07. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2026 earnings at $0.15 EPS.

Separately, Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Price Performance

Shares of THTX stock opened at $1.65 on Thursday. The business’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.45. Theratechnologies has a one year low of $1.08 and a one year high of $2.18. The stock has a market capitalization of $75.87 million, a PE ratio of -16.50 and a beta of 1.26.

Hedge Funds Weigh In On Theratechnologies

A number of institutional investors and hedge funds have recently modified their holdings of THTX. Raymond James Financial Inc. bought a new position in shares of Theratechnologies during the 4th quarter worth approximately $27,000. Bank of America Corp DE boosted its holdings in shares of Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after buying an additional 15,400 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Theratechnologies during the 4th quarter worth approximately $33,000. BNP Paribas Financial Markets bought a new position in shares of Theratechnologies during the 4th quarter worth approximately $36,000. Finally, Virtu Financial LLC bought a new position in shares of Theratechnologies during the 4th quarter worth approximately $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.